The acquisition of the Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the U.S.

Research by a Stanford University team of scientists has shed new light on how and why neural stem cells (NSCs), the cells ...

Industry, academic institutions, suppliers, and regulatory agencies working together can yield state-of-the-art downstream ...

KBI Biopharma says they’re selecting the best technologies to fill gaps in their processes with grassroots help from their ...

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...

Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to ...

Tests in mice suggest glucagon micelle could be used as a responsive system to prevent the onset of insulin-induced deep ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Whereas Biopharma 4.0 prioritizes productivity, Biopharma 5.0 emphasizes environmental and social sustainability.

Researchers recommend verifying success of column-based purification to confirm the presence and availability of the tag on target protein.

In this GEN webinar, our expert speakers will share their journey of implementing intensified technologies and its potential ...

Plant pests are becoming resistant to chemical pesticides. Upping the dose of these pesticides is hardly an option, especially since these substances already raise environmental concerns.